GALT · Galectin Therapeutics Inc · Executive Compensation
$3.19
-0.19 (-5.62%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$321.71M
Shares
100.85M
Volume · Oct 23
195.22K
Avg daily vol (3M)
303.16K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | Chief Executive Officer & President | $1,174,782 |
| Khurram Jamil | M.D., Chief Medical Officer | $1,052,128 |
| Jack W. Callicutt | Chief Financial Officer | $806,564 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | Chief Executive Officer & President | $1,189,674 |
| Khurram Jamil | M.D., Chief Medical Officer | $945,847 |
| Jack W. Callicutt | Chief Financial Officer | $716,945 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | Chief Executive Officer & President | $963,647 |
| Pol F. Boudes | M.D., Former Chief Medical Officer | $770,280 |
| Jack W. Callicutt | Chief Financial Officer | $561,419 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | Chief Executive Officer & President | $974,181 |
| Pol F. Boudes | M.D., Former Chief Medical Officer | $794,577 |
| Jack W. Callicutt | Chief Financial Officer | $566,564 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joel Lewis | Chief Executive Officer & President | $1,167,621 |
| Pol F. Boudes | M.D., Chief Medical Officer | $923,683 |
| Jack W. Callicutt | Chief Financial Officer | $705,918 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Pol F. Boudes | M.D., Chief Medical Officer | $1,082,481 |
| Harold H. Shlevin | Ph.D., Chief Executive Officer & President | $919,336 |
| Joel Lewis | Chief Executive Officer & President | $753,558 |
| Jack W. Callicutt | Chief Financial Officer | $720,372 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Harold H. Shlevin | Ph.D., Chief Executive Officer & President | $1,306,507 |
| Jack W. Callicutt | Chief Financial Officer | $778,124 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Harold H. Shlevin | Ph.D., Chief Executive Officer & President | $1,730,815 |
| Jack W. Callicutt | Chief Financial Officer | $1,266,497 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jack W. Callicutt | Chief Financial Officer | $406,011 |
| Harold H. Shlevin | Ph.D., Chief Executive Officer & President | $405,155 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Henry Brem | member of the Board of Directors | Appointed | 2026-03-17 |
| Marc Rubin | Board of Directors | Resigned | 2026-01-12 |
| Pol Boudes | Chief Medical Officer | Resigned | 2024-08-01 |
| Khurram Jamil | Chief Medical Officer | Appointed | 2024-08-01 |
Leadership
- Joel Lewis CEO, Board Member
- Jack W. Callicutt CFO
- Benjamin S. Carson Board Member
- Dr. Henry Brem Board Member
- Elissa J. Schwartz Board Member
- Gilbert F. Amelio Board Member
- Gilbert S. Omenn Board Member
- Harold H. Shlevin Board Member
- Henry Brem Board Member
- Kary Eldred Board Member
- Kevin D. Freeman Board Member
- Richard A. Zordani Board Member
- Richard E. Uihlein Board Member
Key facts
CIK
1133416
CUSIP
363225202
13F (30d)
15 filings
15 filers
Visit website
Investor relations